Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-06-28
2005-06-28
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S247000, C514S002600, C544S224000
Reexamination Certificate
active
06911439
ABSTRACT:
Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
REFERENCES:
patent: 4018913 (1977-04-01), Okamoto et al.
patent: 4018915 (1977-04-01), Okamoto et al.
patent: 4036955 (1977-07-01), Okamoto et al.
patent: 4041156 (1977-08-01), Okamoto et al.
patent: 4046876 (1977-09-01), Okamoto et al.
patent: 4055636 (1977-10-01), Okamoto et al.
patent: 4055651 (1977-10-01), Okamoto et al.
patent: 4070457 (1978-01-01), Okamoto et al.
patent: 4073914 (1978-02-01), Kikumoto et al.
patent: 4085057 (1978-04-01), Masuda et al.
patent: 4096255 (1978-06-01), Kikumoto et al.
patent: 4104392 (1978-08-01), Okamoto et al.
patent: 4438122 (1984-03-01), Holmwood et al.
patent: 4505910 (1985-03-01), Bagli
patent: 4518600 (1985-05-01), Holmwood et al.
patent: 4544402 (1985-10-01), Schnurbusch et al.
patent: 4559345 (1985-12-01), Gomarasca et al.
patent: 4672065 (1987-06-01), Spatz
patent: 4908368 (1990-03-01), Murase et al.
patent: 4959364 (1990-09-01), Mueller et al.
patent: 4992439 (1991-02-01), Meanwell
patent: 5030644 (1991-07-01), Baldwin et al.
patent: 5120734 (1992-06-01), Klausener et al.
patent: 5238934 (1993-08-01), Knuppel et al.
patent: 5278184 (1994-01-01), Artico et al.
patent: 5510332 (1996-04-01), Kogan et al.
patent: 5580868 (1996-12-01), Lunkenheimer et al.
patent: 5770573 (1998-06-01), Arrhenius et al.
patent: 5814643 (1998-09-01), Duggan et al.
patent: 5861429 (1999-01-01), Sato et al.
patent: 5925644 (1999-07-01), Jakobi et al.
patent: 5942504 (1999-08-01), Grobelny
patent: 5955491 (1999-09-01), Sohda et al.
patent: 5962479 (1999-10-01), Chen
patent: 5972946 (1999-10-01), Murata et al.
patent: 6005117 (1999-12-01), Wehner et al.
patent: 2241149 (1997-07-01), None
patent: 2259224 (1998-01-01), None
patent: 19536891 (1997-04-01), None
patent: 2655636 (1997-06-01), None
patent: 19548709 (1997-07-01), None
patent: 19654483 (1998-01-01), None
patent: 19713000 (1998-10-01), None
patent: 116494 (1984-08-01), None
patent: 0 147 211 (1985-07-01), None
patent: 0 288 176 (1988-10-01), None
patent: 0330506 (1989-08-01), None
patent: 0 526 348 (1993-02-01), None
patent: 0 535 521 (1993-04-01), None
patent: 0330506 (1999-08-01), None
patent: 1500063 (1978-02-01), None
patent: 59212480 (1984-12-01), None
patent: WO 92/16549 (1992-10-01), None
patent: WO 93/12809 (1993-07-01), None
patent: WO 96/01644 (1996-01-01), None
patent: WO 96/22966 (1996-08-01), None
patent: WO 96/32383 (1997-04-01), None
patent: WO 97/23451 (1997-07-01), None
patent: WO 98/00395 (1998-01-01), None
patent: WO 98/33783 (1998-08-01), None
patent: 9853814 (1998-12-01), None
patent: WO 98/53817 (1998-12-01), None
patent: WO 99/06390 (1999-02-01), None
patent: WO 99/06391 (1999-02-01), None
patent: WO 99/06431 (1999-02-01), None
patent: WO 99/06432 (1999-02-01), None
patent: WO 99/06433 (1999-02-01), None
patent: WO 99/10312 (1999-03-01), None
patent: WO 99/10313 (1999-03-01), None
patent: WO 99/37605 (1999-07-01), None
patent: WO 99/37618 (1999-07-01), None
patent: WO 99/52898 (1999-10-01), None
Chem. Abstract 130:52724 structures for WO 9853814 dated Dec. 1998.
Chem. Abstract 69:676 structures for Jaeger et al, Chem.Berichte 101/8,2762-70(1968).
Chem.Abstract 105:97885 for structure, Marr-Leisy et al, Colloid and Polymer Sc., 263/10,791-8(1985).
Chem. ASbstract 102:149279 for streucture of JP 59212480 dated Dec. 1984.
Chem. Abstract 102:24642 for structures of EP 116494 dated Aug. 1984.
U.S.applications Nos., 09910685 filed Jul. 20, 2001; 09910466 filed Jul. 19, 2002; 10218445 filed Aug. 15, 2002;2002/0052375 filed 7/1901.
Hladon, Buguslaw et al., In Vitro cytostatic activity of some amino acid 4-N-substituted cytosines,Arch. Immunol. Ther. Exp. (1992), 40(2), 145-50. (Abstract).
Hoffman, Seigfried; Schubert, Herman; Nitsche, Klaus, N-Pyrimidinylamino acids. III. N-(oxopyrimidinyl) derivatives of neutral amino acids,Z. Chem. (1972), 12(1) 21-2, Coden: Zeceal (Abstract).
Teranishi, Katsunoir; Goto, Toshio, Synthesis and Chemiluminescense of Coelenterazine (Oplophorus luciferin) analogs,Bull. Chem. Soc. Jpn. (1990), 63(11), 3132-40 (Abstract).
Abraham, W.M., et al. “β4-Integrins Mediate Antigen -induced Late Bronchial Responses and Prolonged Airway Hyperresponsiveness in Sheep.”J. Clin. Invest. 93: 776-787 (1994).
Bao, L., et al. “Correlation of VLA-4 integrin expression with metastatic potential in various human tumour cell lines.”Diff. 52: 239-246 (1993).
Baron, J.L., et al. “Surface Expression of α4 Integrin by CD4 T Cells is Required for Their Entry into Brain Parenchyman.”J. Exp. Med. 177:57-68 (1993).
Baron, J.L., et al. et al. “The Pathogenesis of Adeoptive Murine Autonimmune Diabetes Requires an Interaction between α4-Integrins and Vascular Cell Adhesion Molecule-1.”J. Clin. Invest. 93: 1700-1708 (1994).
Burkly, L.C., et al. “Protection Against Adoptive Transfer of Autoimmune Diabetes Mediated Through Very Late Antigent-4 Integrin.”Diabetes. 43: 529-534 (1994).
Cybulsky, M.I., et al. “Endothelial Expression of a Mononuclear Leukocyte Adhesion Molecule During Atherogenesis.”Science. 251: 788-791 (1991).
Elices, M.J., et al. “Expression and Functional Significance of Alternatively Spliced CS1 Fibronecting in Rheumatoid Arthritis Microvasculature.”J. Clin. Invest. 93: 405-416 (1994).
Elices, M.J., et al. “VCAM-1 on Activated Endothelium Interacts with the Leukocyte Integrin VLA-4 at a Site Distinct from the CLA-4/Fibronectin Binding Site.”Cell. 60: 577-584 (1990).
Hamann, A., et al. “Role of α4-Integrins in Lymphocute Homing to Mucosal Tissues in Vivo.”J. Immunology. 152: 3283-3292 (1994).
Hladon, B., et al. “In Vitro cytostatic activity of some amino acid 4-N-substituted cytosines”Arch. Immunol. Ther. Exp.40(2): 145-150 (1992). (Abstract).
Hoffman, S., et al. “N-Pyrimidinylamino acids. III. N-(oxopyrimidinyl) derivatives of neutral amino acids.”Z. Chem. 12(1): 21-22 (1972), Coden: Zeceal (Abstract).
Kawaguchi, S., et al. “VLA-4 Molecules on Tumor Cells Initiate an Adhesive Interaction with VCAM-1 Molecules on Endothelial Cell Surface.”Japanese J. Cancer Res. 83: 1304-1316 (1992).
Lauri, D., et al. “Decreased adhesion to endothelial cells and matrix proteins of H-2Kbgene transfected tumour cells.”British J. Cancer. 68: 862-867 (1993).
Li, H., et al. “An Atherogenic Diet Rapidly Induces VCAM-1, a Cytokine-Regulatable Mononuclear Leeukocyte Adhesion Molecule, in Rabbit Aortic Endothelium.”Arterioscler. Thromb. 13(2): 197-204 (1993).
Mulligan, M.S., et al. “Role of β1, β2 Integrins and ICAM-1 in Lung Injury after Deposition of IgG and IgA Immune Complexes.”J. Immunol. 150(6): 2407-2417 (1993).
Okarhara, H., et al. “Involvement of Very Late Activation Antigens 4 (VLA-4) and Vascular Cell Adhesion Molecular 1(VCAM-1) in Tumor Necrosis Factor α Enhancement of Experimental Metastasis.”Can. Res. 54: 3233-3236 (1994).
Osborn, L. “Leukocyte Adhesion to Endothelium in Inflammation.”Cell. 62: 3-6 (1990).
Paavonen, T., et al. “In Vivo Evidence of the Role of α4β1-VCAM-1 Interactions in Sarcoma, but not in Carcinoma Extravasation.”Int. J. Can. 58: 298 (1994).
Paul, L.C.,et al. “Monoclonal Antibodies Against LFA-1 and VLA-4 Inhibit Graft Vasculitis in Rat Cardiac Allografts.”Transpl. Proceed. 25(1): 813-814 (1993).
Postigo, A.A., et al. “Increased Binding of Synovial T Lumphocytes from Rheumatoid Arthritis
Ashwell Susan
Dressen Darren B.
Grant Francine S.
Konradi Andrei W.
Kreft Anthony
Elan Pharmaceuticals Inc.
Foley & Lardner LLP
Patel Sudhaker B.
Raymond Richard L.
Wyeth
LandOfFree
Heteroaryl, heterocyclic and aryl compounds which inhibit... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heteroaryl, heterocyclic and aryl compounds which inhibit..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heteroaryl, heterocyclic and aryl compounds which inhibit... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3464072